ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CGEN vs PALI // FORWARD P/E MULTIPLE

Compugen Ltd. (NASDAQ) VS. Palisade Bio Inc. (NASDAQ) • 15-METRIC TALLY: CGEN 4 — PALI 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEN VS. PALI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CGEN PALI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 CGEN /roic <GO>
EV/EBITDA & P/E Valuation 3.2x — — TIE /valuation <GO>
Free Cash Flow Yield 16.24% -5.23% +21.47 CGEN /fcf-yield <GO>
Operating Margin 43.10% — — TIE /operating-margins <GO>
Net Profit Margin 48.60% — — TIE /net-margins <GO>
Revenue Growth (YoY) 161.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 CGEN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.1 30.1 +11.00 CGEN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE 4.6x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $193.0M $207.4M -$14.4M PALI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CGEN REV PALI REV CGEN GROSS % PALI GROSS % CGEN FCF PALI FCF
FY 2025 $72.8M $0 87.3% — $31.3M -$10.8M
FY 2024 $27.9M $0 71.5% — $49.5M -$12.2M
FY 2023 $33.5M $250.0K — — -$35.9M -$11.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEN // BETA —
PALI // BETA —